Search Results

Mobius Therapeutics™, LLC, a St. Louis-based perioperative ophthalmic pharmaceutical company, will initiate a series of professional education sessions, focused on how end users of Mitosol® can achieve compliance with USP <800>, the soon to be implemented and enforced standards for control of hazardous drugs in healthcare facilities.

Mobius Therapeutics™, LLC, a St. Louis-based perioperative ophthalmic pharmaceutical company, has been issued US Patent #11,540,977, Injection Apparatus and Method of Use.

Mobius Therapeutics™, LLC, a St. Louis-based perioperative ophthalmic pharmaceutical company, will initiate a social media presence featuring interviews and live streaming of customers to support the value proposition of its flagship product, Mitosol®.

Arsham Sheybani , MD of Washington University and Lori Pacheco of Orbis to discuss Mitosol®.

Mobius Therapeutics™, LLC , the St. Louis -based makers of Mitosol ® (mitomycin for solution) 0.2 mg/vial Kit for Ophthalmic Use , has maintained production and inventory of Mitosol ® , recognizing the non-elective nature of the patie

By expanding this orphan drug indication, Mobius Therapeutics may now assume the benefits of orphan drug designation for new and evolving MIGS procedures used in the treatment of glaucoma.

Recognizing the effect that COVID-19 has had on the routine of its customer base, Mobius Therapeutics™, LLC, the St. Louis-based makers of Mitosol® Kit for Ophthalmic Use, is renewing efforts and reassigning resources to support customer needs related to Continuing Education and Customer Support.

Stryker (NYSE: SYK) announced today it has completed the acquisition of Mobius Imaging, LLC, a leader in point-of-care imaging technology, and its sister company, GYS Tech, LLC (DBA Cardan Robotics).

This is the first Mobius Airo CT to be clinically integrated to the Stryker NAV3i for spine surgeries

Vascular Dynamics, Inc. (VDI) announced that two-year results from a study assessing its MobiusHD device to treat patients with chronic heart failure were presented today at the Technology and Heart Failure Therapeutics (THT) 2023 meeting in Boston.